ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

Publications

Dinger Jürgen, Heinemann Lothar A , Do Minh Thai, Assmann Anita, Breast cancer risk associated with different HRT formulations: a register-based case-control study. BMC Women's Health. 2006; 6:13.
Dinger Jürgen, Assmann Anita, Heinemann Lothar A , International active surveillance study of women taking oral contraceptives (INAS-OC). Pharmacoepidemiology and Drug Safety. 2006; 15: S132.
Dinger Jürgen, Assmann Anita, Heinemann Lothar A , The impact of obesity on the contraceptive reliability of oral contraceptives. Pharmacoepidemiology and Drug Safety. 2006; 15: S140.
Heinemann Lothar A , Moore C, Dinger Jürgen, Stoehr D, Sensitivity as outcome measure of androgen replacement: the AMS scale. Health and Quality of Life Outcomes. 2006; 4:23.
Heinemann Lothar A , Dinger Jürgen, The menopause rating scale (MRS) as outcome measure for hormone treatment. Pharmacoepidemiology and Drug Safety. 2006; 14: S44.
Dinger Jürgen, Zimmermann T, Heinemann Lothar A , Stoehr D, Quality of life and hormone use: new validation results of MRS scale. Health and Quality of Life Outcomes. 2006; 4:32.
Dinger Jürgen, Heinemann Lothar A , Do Minh Thai, Assmann Anita, Thiel C, The risk of gynaecological cancers associated with different HRT formulations. A nested case-control study in the German Cohort Study on Women’s Health. Geburth Frauenheilk. 2006; 66:145-155.
Heinemann Lothar A , Dinger Jürgen, Klinische Studien – eine Evidenzfalle?. Frauenarzt. 2006; 47:331-35.l.
Heinemann Lothar A , Assmann Anita, Dinger Jürgen, The risk of venous thromboembolism (VTE) in oral contraceptives: a new lesson. Pharmacoepidemiology and Drug Safety. 2006; 15: S24.
Schellschmidt I, Do Minh Thai, Dinger Jürgen, Factors influencing return to fertility after use of oral contraceptives. Pharmacoepidemiology and Drug Safety. 2006; 15: S25.
Dinger Jürgen, Assmann Anita, Heinemann Lothar A , The European active surveillance study on oral contraceptives (EURAS-OC): final results after more than 130,000 WY of observatio. Pharmacoepidemiology and Drug Safety. 2006; 15: S26.